||combined alpha and beta receptor blocker; antihypertensive
- decreases blood pressure (alpha blockade)
- decreases HR, contractility, myocardial oxygen requirements (beta blockade)
- 5-20 mg IV direct initially; additional doses of 40-80 mg may be given at 10 minute intervals
- 2 mg/min with the rate of infusion adjusted to supine BP
- infusion of 0.5 - 1.0 mg/kg/hr titrated to effect
- Bolus dose:
- 5-20 mg IV direct over a 2 minute period
- bolus should be diluted to a concentration of 1 mg/mL
- IV Infusion:
- 500 mg/100 mL in D5W, NS, RL
- decreased contractility, cardiac output
- ventricular arrhythmias (including PVCs)
- excessive drops in BP - especially orthostatic hypotension (patients should be kept supine for 3 hours after administration)
- parasthesia (mild, transient tingling of scalp or skin)
- dyspnea, bronchospasm
- pain at injection site
- caution in left ventricular dysfunction, bronchospastic disease, pheochromocytoma (additional alpha blockade required), hepatic dysfunction
- labetalol + nitroglycerin = additive hypotensive effect
- labetalol + beta2 agonists = decreased bronchodilation
- HR and rhthym
- breath sounds (presence of bronchospasm or wheezing)
- cardiac index
- May be administered IV direct by an approved nurse in the CCTC.
- May be titrated by an approved nurse in CCTC.
- Should be infused via a central line.
- Continuous infusion must be administerd via an infusion pump.
- Should not be infused via the proximal injectate port (blue) of the Swan Ganz catheter.
- Patient requires placement of an arterial line to monitor BP.